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Introduction: A more effective tuberculosis (TB) vaccine is needed to eliminate TB disease. Many new
vaccine candidates enhance the immunogenicity of the existing vaccine, Bacillus CalmetteeGuerin (BCG).
Understanding BCG induced immune variation is key to developing a new vaccine.
Aims: We aimed to establish if individual-level covariates were associated with cell-mediated immune
response (interferon gamma (IFN-g)) at vaccine trial enrolment (baseline) in a long-term retrospective
analysis (LTR) and after BCG vaccination in a short-term prospective analysis (STP).
Methods: Four covariates were analysed: gender, country, BCG vaccination history and monocyte/
lymphocyte cell count ratio. Univariable and multivariable linear regression were conducted on IFN-g
response at baseline for LTR, and area under the curve (AUC), 24 week and peak IFN-g response for STP.
Results: Previous BCG vaccination was strongly associated with higher IFN-g response at baseline (LTR
analysis) (p-values < 0.05). Being male showed a weak association with higher baseline response
(p-value ¼ 0.1). BCG revaccination was strongly associated with a larger response increase than primary-
vaccination (AUC & peak p-values < 0.01), but did not differ at 24 weeks (STP analysis). All other
covariates were non-signiﬁcant (p-values > 0.1).
Conclusion: This analysis suggests that previous BCG vaccination and gender are associated with durable
IFN-g responses. Vaccine trials may need to stratify by BCG vaccination history and gender.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculosis disease (TB) caused by the organism Mycobacte-
rium tuberculosis (M.tb), remains a substantial global health prob-
lemwith approximately 9 million people developing active disease
and 1.5 million TB-related deaths in 2013 [1]. This is despite nearlyodes).
Ltd. This is an open access article u70 years of widespread use of the only licensed TB vaccine, Bacillus
CalmetteeGuerin (BCG), a live attenuated strain of Mycobacterium
bovis, which has exhibited variable efﬁcacy [2]. Novel TB vaccines
are considered an essential tool to meet the WHO goal of TB
elimination by 2050 [3,4], and many candidates utilise a BCG
prime-boost strategy.
It has been proposed that the observed variation in BCG efﬁcacy
could be attributed to individual-level factors that inﬂuence host
mycobacterial-speciﬁc immune responses [5,6]. Factors that have
been shown to be consistent in their inﬂuence of such responses
include: latitude, which is known to be associated with varyingnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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speciﬁc sensitization of the immune system through previous BCG
vaccination [8]. Additional factors that have shown consistent in-
ﬂuence include age at vaccination and BCG strain [5].
Another factor that may inﬂuence the mycobacterial-speciﬁc
immune response is gender. TB prevalence surveys report a
higher occurrence of disease in males than females [9], which is
thought in part to be due to differences in the immune response
between the sexes [10], in addition to social aspects [11]. However,
so far, investigations into the effects of gender on the mycobacterial
immune response have shown equivocal results [12,13] and few TB
vaccine immunogenicity or efﬁcacy trials have reported results
stratiﬁed by gender.
In addition, recent evidence has shown that the ratio of host
monocyte to lymphocytes cells (ML ratio) was associated with risk
of TB disease [14e16]. Naranbhai et al. observed that in HIV posi-
tive, South African adults on combination antiretroviral therapy,
this relationship was nonlinear, i.e. low and high, compared to
moderate, ML ratios were associated with a higher risk of TB [14].
Little investigation has been made into how ML ratio may affect
mycobacterial-speciﬁc immune responses and further insight into
this relationship could potentially inform targeted TB vaccine
strategies.
New detailed longitudinal immune response data to BCG
vaccination has recently become available due to an increase in
research into new TB vaccines in which BCG vaccination was used
as a control [17]. These detailed data have the potential to give new
insights into how individual-level factors alter the immune
response to BCG.
Our aimwas to consider how individual-level factors affect BCG
immunogenicity as measured by tuberculin puriﬁed protein de-
rivative (PPD) stimulated interferon gamma (IFN-g) response
following vaccination. Utilizing new immunological data allowed
us to provide a more detailed analyses of the immune response
than previous studies, which have focused on long-term responses
with less detail of short-term dynamics.
2. Methods
In this study, two analyses were performed on data from par-
ticipants included in new TB vaccine (BCG-booster) trials in which
participants were given a new TB vaccine or BCG as a control
measure. The data from the BCG control arms were used in this
analysis.
Our ﬁrst analysis aimed to determine which individual level
covariates were associated with increased PPD antigen-speciﬁc
IFN-g immune response at enrolment to the trials. In this anal-
ysis, IFN-g responsesmeasured at enrolment to the trial (and before
BCG vaccination was administered) is referred to as the ‘baseline
response’. This was a cross-sectional analysis of previously BCG
vaccinated or BCG-naïve trial participants, and is referred to as the
‘long-term retrospective’ or ‘LTR’ analysis.
The second analysis aimed to determine which covariates were
associated with IFN-g immune response over a short period,
following BCG vaccination. This analysis was conducted using data
from the prospective follow-up of study participants, who had
either been revaccinated or primary-vaccinated with BCG imme-
diately following baseline screening and were followed up for 24
weeks post vaccination. This is referred to as the ‘short-term pro-
spective’ or ‘STP’ analysis.
2.1. Data and materials
In this study we used data from seven vaccine trials involving
BCG (Table 1). The available data were on HIV negative and M.tbnaïve participants (see references in Table 1 for HIV and M.tb
latency testing procedures). Data on haematological parameters
were based on routine laboratory haematology testing at baseline
and only those participants with values within normal limits were
included in clinical trials.
IFN-g response was measured using a standardized ex vivo
IFN-g Enzyme-Linked ImmunoSpot (ELISPOT) assay which quan-
tiﬁes IFN-g secreting CD4þ T cells as spot forming units (SFU) per
million peripheral blood mononuclear cells (PBMCs) using PPD as a
stimulant. The same ELISPOT method including plates, antibody
kits, antigens, developing reagents, washing method, ELISPOT
reader and ELISPOT counting method were used across all UK trials
and all South African trials. South African researchers visited the UK
laboratory for ELISPOT training and reagents for the ELISPOT assay
were shipped from UK to South Africa for these studies. As these
BCG studies were conducted as part of a series of Phase I clinical
trials with MVA85A all lab protocols and lab reagents were
harmonized as far as possible between UK trials and between UK
and South African trial. For the exact laboratory methodology see
[17e20].
2.2. Covariates
The four individual-level factors (covariates) included in this
analysis were country (UK or South Africa), gender, BCG vaccination
history at baseline and baseline ML ratio. ML ratio data were not
available for three of the studies (two UK trials and the South Af-
rican trial, Table 1). For details on how BCG-vaccination history was
determined see original trial methods [17e20]. BCG vaccination
history was categorised into “never” and 10 year time-periods since
vaccination with the reference group as 1e9 years since BCG
vaccination. Age was not included as a covariate as it was colinear
with BCG vaccination history.
2.3. Statistical analysis
The analyses were performed using linear regression. Firstly, a
univariable model analyses was conducted referred to as the ‘un-
adjusted’ analysis, followed by multivariable model; the ‘fully
adjusted’ analysis. Analysis was conducted using R [21]. A p-value
of 0.05 was considered as strong evidence for an association with
the outcome.
All outcomes were log transformed (natural log) as data were
right-skewed and the residuals veriﬁed to justify this trans-
formation. The effect measures are the anti-logged regression slope
parameters, the associated 95% conﬁdence interval (CI) and
p-value. For the categorical covariates (country, gender and BCG
vaccination history), these represent the ratio of the geometric
means (GM) of the IFN-g response outcome variable compared to
the reference group. For the continuous covariate, ML ratio, the
effect measure represents the increase in GM of the IFN-g response
outcome variable for an increase in 0.1 ML ratio (as ML ratio is
bound by zero and one), assuming a linear trend in ML ratio.
Additionally, due to previous research that found a nonlinear
relationship to exist between ML ratio and risk of TB disease [14],
both linear and quadratic regressionmodels were ﬁtted to establish
if a similar relationship existed between IFN-g response and ML
ratio (see Supplementary Material for example, Table S2). Analysis
of variance (ANOVA) was used to assess if a non-linear relationship
more adequately described this association.
2.3.1. Long-term retrospective (LTR) outcome variables
Baseline IFN-g responses were used as the outcome variable in
the long-term analysis. All four individual-level covariates were
considered in the analysis. In the BCG vaccination history covariate,
Table 1
Demographic and trial information for participants included in long-term retrospective (LTR) and short-term prospective (STP) analyses. Trial information was split by BCG
vaccine history where possible.
Vaccine
trials no.
No. of
participants
Country Male (%) Median age
(IQR) years
Previous BCG
vaccination (median
years since (IQR))
Blood haematological:
median (IQR) % of cells
in whole blood
Median ML
ratio (IQR)
Included in
LTR/STP
analysis
Reference
Monocytes Lymphocytes
NCT00480688 11 UK 3 (27%) 25 (8.5) None (NA) 0.30 (0.15) 1.76 (0.43) 0.20 (0.05) LTR/STP [17]
NCT00480714 6 UK 2 (33%) 25 (0) None (NA) 0.36 (0.21) 1.90 (0.32) 0.19 (0.16) LTR/STP [17]
NA* 14 UK 4 (29%) 23.5 (9) None (NA) 0.56 (0.18) 1.89 (0.41) 0.31 (0.18) LTR/STP [36]
14 7 (50%) 23 (8.5) Yes (15 (0.6)) 0.57 (0.18) 1.66 (0.34) 0.29 (0.07)
NCT00654316 13 UK 4 (29%) 25 (11) Yes (12 (11)) 0.34 (0.17) 1.53 (0.42) 0.24 (0.10) LTR/STP [18]
NCT00427453 10 UK 3 (30%) 24 (7.3) None (NA) NA NA NA LTR [19]
NCT00427830 15 UK 7 (47%) 27 (10.5) Yes (21 (7)) NA NA NA LTR [17]
NCT00460590 4 South
Africa
2 (50%) 40.5 (4.8) None (NA) NA NA NA LTR [20]
14 3 (21%) 33.5 (12) Yes (33.5 (12)) NA NA NA
Aggregated 101 e 35 (35%) 26 (11) 21 (17.3) 0.41 (0.24) 1.70 (0.51) 0.22 (0.11) e e
* Trial number was not available for this trial at time of analysis. Three participants from the ﬁrst four trials (those included in both the LTR and STP analyses) did not have
full STP data, so were only included in the LTR. NA ¼ not available. IQR ¼ Interquartile range; ML ¼ Monocyte/lymphocyte.
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group “never” representing those who were BCG naïve at baseline.
2.3.2. Short-term prospective (STP) outcome variables
To investigate the short-term response, IFN-g responses at
baseline and 4, 8 and 24weeks post BCG vaccinationwere used and
summarized using the following three statistics as outcome vari-
able: area under the curve (AUC), peak and the 24week (referred to
as ‘sustained’) IFN-g responses. The AUC summarises the total
change in IFN-g response over 24 weeks post BCG vaccination and
was calculated using the R package “Kulife” [22].
For the STP analysis, unadjusted and fully adjusted regression
was conducted separately for the three outcomes. For the STP
analysis, an additional analysis was also carried out for peak and 24
week response, whereby adjustment for baseline IFN-g responses
was conducted, known as the ‘partially adjusted’ analysis. This was
not adopted for the AUC outcome variable, as the AUC calculation is
standardized by the baseline value, so adjustment for the effect is
not necessary.
In the STP analysis, the categories deﬁned for the BCG vaccina-
tion history covariate correspond to years since previous BCG
vaccination before receiving BCG at enrolment into the trial. The
group ‘never’, corresponds to being ‘primary vaccinated’ atTable 2
Long-term retrospective (LTR) analysis: results of the linear regression analysis on basel
Covariates (n) Geometric mean
of IFN-g response
Unadjusted GM ratio (95% C
Country
South Africa (18) 65.62 1 e
UK (83) 47.56 0.73 (0.32, 1
Gender
Female (66) 39.82 1 e
Male (35) 78.45 1.97 (1.03, 3
BCG vacc history
1e9 yrs (8) 133.54 1 e
10e19 yrs (13) 121.28 0.91 (0.25, 3
20e29 yrs (19) 80.58 0.60 (0.18, 2
30 þ yrs (12) 94.93 0.71 (0.19, 2
Never (49) 24.27 0.18 (0.06, 0
ML ratio (58) 0.89z (0.58, 1
As an example of the GM of the IFN-g response byML ratio two values were chosen from th
using the unadjusted GM ratio value in the above table. As such, the GM for the IFN-g resp
IFN-g ¼ Interferon gamma; vacc ¼ vaccination; GM ¼ geometric mean; yrs ¼ years; ML
* Adjusted for all variables in the model except ML ratio.
y p-value for all categories of BCG vaccination history covariate using an ANOVA summ
z Represents the value of the change in GM of the IFN-g response for an increase in 0enrolment. As all trials used in the STP analysis were UK based, all
individual-level covariates except country were included.
3. Results
101 participants were included in this analysis (Table 1). Seven
vaccine clinical trials were used in the LTR analysis; four of those
also had data available for the STP analysis (Table 1 and Table S1).
Participants were either vaccinated with BCG (56 participants), at a
median of 21 years (interquartile range (IQR) ¼ 17.3) before base-
line or BCG naïve at baseline (45 participants). The median of the
ML ratiowas 0.22 (IQR¼ 0.11). The distribution of ML ratio amongst
the population can be found in Figure S1.
3.1. Long-term retrospective (LTR) analysis
All 101 participants were included in the LTR analysis. All
covariates were included in the fully adjusted analysis, except for
ML ratio as data on this measure were not available for some of the
trials (data were only available for 58 participants (Table 1)).
For male participants, the unadjusted GM ratio of the IFN-g
response at baseline was nearly twice that of females (GM ratio
1.97, 95% CI (1.03, 3.77)) (Table 2), and remained weakly associatedine IFN-g responses (SFU/mill cells) against individual-level covariates.
I), p-value Fully adjusted* GM ratio (95% CI), p-value
1 e
.65), 0.63 1.02 (0.41, 2.55), 0.97
1 e
.77), 0.04 1.76 (0.96, 3.25), 0.07
1
.28) 0.74 (0.20, 2.70)
.01) 0.57 (0.17, 1.93)
.62) 0.72 (0.17, 3.13)
.54), <0.001y 0.18 (0.06, 0.52), <0.001y
.38), 0.61 e e
e range ofML ratio (Table 1) to represent high and low values and the GM calculated
onse for a ML ratio of 0.1 and 0.3 were 52.03 and 50.88, respectively. Abbreviations:
¼ Monocyte/lymphocyte.
ary.
.1 of ML ratio.
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ratio 1.76, 95% CI (0.96, 3.25)).
For BCG-naïve participants (‘never’), a GM ratio of their IFN-g
response at baseline of 0.18 (95% CI (0.06, 0.54)) was found,
compared to that of the reference group of 1e9 years since BCG
vaccination (Table 2) and remained strongly associated after full
adjustment (GM ratio 0.18, 95% CI (0.06, 0.52)). GM IFN-g response
was similar for 1019, 2029 and 30þ years since BCG vaccination,
compared to 1e9 years since BCG vaccination (Table 2).
There was no evidence of an association between IFN-g
response at baseline andML ratio in the linear or quadratic analyses
(Table 2, Table S2). Neither was there an association between IFN-g
response and country (Table 2).
3.2. Short-term prospective (STP) analysis
Data from 55 participants, all UK adults, were available for the
STP analysis. The IFN-g responses over the 24 week follow-up
period, by primary or revaccination status, are shown in Figure 1.
All analyses (unadjusted, partially and fully adjusted) suggested
there was no association between gender or ML ratio and AUC
(Table 3), 24 week response (Table 4) or peak response (Table 5).
Being primary-vaccinated (‘never’ in Table 3) was strongly
associated with a lower AUC in the unadjusted analysis with a GM
ratio of 0.16 (95% CI (0.06, 0.44)) (Table 3 and Figure 1). This asso-
ciation remained strong after adjustment for baseline IFN-g
response, gender and ML ratio (GM ratio 0.22, 95% CI (0.07, 0.68)).
No other groups in the BCG vaccination history covariate were
associated with AUC.
BCG vaccination history was strongly associated with 24 week
response in the unadjusted analysis, speciﬁcally: primary-
vaccinated participants had lower 24 week responses (GM ratio
0.14, 95% CI (0.06, 0.36)) (‘never’ in Table 4) compared to the
reference group. After full adjustment, this association remained
but was weaker (GM ratio 0.29, 95% CI (0.07, 1.12)). The partially
adjusted analysis showed changes in the GM ratio for all covariates
(Table 4). Most notably, the GM ratio for those who were primaryFigure 1. Longitudinal IFN-g responses for the Short-term prospective (STP) analysis for
represents the median values of each group at each time point. X-axis is not to scale. Abbrev
mononuclear cells. (For interpretation of the references to colour in this ﬁgure legend, thevaccinated increased from 0.14 (95% CI (0.06, 0.36)) to 0.25 (95% CI
(0.09, 0.69)) compared to the reference group in the unadjusted
and partially adjusted analyses, respectively.
Primary-vaccinated participants had lower peak IFN-g response
compared to the reference group in the unadjusted analysis (GM
ratio 0.24, 95% CI (0.14, 0.39)) (Table 5). This remained after full
adjustment for all covariates (GM ratio 0.32, 95% CI (0.15, 0.68))
(Table 5). The partially adjusted analysis did not signiﬁcantly
change this value (GM ratio 0.29, 95% CI (0.16, 0.51)), indicating a
minimal affect of baseline response on the association between
BCG vaccination history and peak response (Table 5).
4. Discussion
We investigated the impact of multiple individual-level cova-
riates on the mycobacterial-speciﬁc immune response pre- and
post- BCG vaccination. Being male or previously BCG vaccinated
was associated with higher IFN-g response at baseline. BCG
revaccination resulted in a larger initial increase in immune
response than primary-vaccinated participants, but response was
not signiﬁcantly different at 24 weeks. All other covariates (country
and ML ratio) were non-signiﬁcant.
Differences in TB disease notiﬁcation rates between the gen-
ders have been well documented and are thought to be a result of
both social and biological factors [10]. In our analysis we found a
weak association between male gender and higher IFN-g levels at
baseline in the long term retrospective (LTR) analysis. This could
be linked to sex hormones causing differences in gender-
associated immune responsiveness, speciﬁcally those of IFN-g
[10,23]. Our results are consistent with previous studies that show
women have signiﬁcantly lower IFN-g response after PPD stimu-
lation than men (after adjustment for age, BMI andM.tb infection)
[13] as well as less strong tuberculin skin testing results [24].
However, these results remain somewhat surprising as reported
disease incidence tends to be higher in men [9]. This could imply
that disease burden differences may be due to behavioural, rather
than biological, reasons or that a balanced immune response is55 participants. BCG revaccinated (A) and primary-vaccinated (B). The bold red line
iations: IFN-g ¼ Interferon gamma; SFU ¼ spot forming unit; PBMC ¼ peripheral blood
reader is referred to the web version of this article.)
Table 3
Short-term prospective (STP) analysis: results of the linear regression analysis on AUC.
Area under the curve (AUC)
Covariates (n) Geometric mean of AUC Unadjusted GM ratio (95% CI), p-value Fully adjusted* GM ratio (95% CI), p-value (n ¼ 43y)
Baseline IFN-g response (55) 329.03 1.00 (0.99, 1.01), 0.49 1.00 (0.99, 1.01), 0.76
Gender
Female (36) 280.13 1 e 1 e
Male (19) 446.30 1.59 (0.73, 3.49), 0.24 1.04 (0.55, 1.96), 0.91
BCG vacc historyz
1e9 yrs (8) 1156.66 1 e 1 e
10e19 yrs (10) 579.88 0.50 (0.15, 1.63) 0.45 (0.16, 1.27)
20e29 yrs (7) 384.62 0.33 (0.09, 1.21) 0.70 (0.19, 2.50)
Never (30) 187.84 0.16 (0.06, 0.44), 0.002x 0.22 (0.07, 0.68), 0.01
ML ratio (43) 1.16¶ (0.85, 1.58), 0.33 1.09¶ (0.82, 1.45), 0.53
Using a similar analysis of GM of IFN-g response byML ratio as in Table 2; GM for the AUC for aML ratio of 0.1 and 0.3were 111.57 and 115.01, respectively. Abbreviations: IFN-
g ¼ Interferon gamma; vacc ¼ vaccination; GM ¼ geometric mean; yrs ¼ years; ML ¼ Monocyte/lymphocyte.
* Adjusted for all variables in the model.
y Due to missing ML ratio data.
z Prior to BCG vaccination in trial.
x p-value for all categories of BCG vaccination history covariate using an ANOVA summary.
¶ The value of the change in GM of the AUC for an increase in 0.1 of ML ratio.
Table 4
Short-term prospective (STP) analysis: results of the linear regression analysis on 24 week IFN-g response.
24 week IFN-g response
Covariates (n) Geometric mean of 24
week IFN-g response
Unadjusted GM ratio (95% CI),
p-value
Partially adjusted (for baseline IFN-g
response) GM ratio (95% CI), p-value
Fully adjusted* GM ratio
(95% CI), p-value (n ¼ 43y)
Baseline IFN-g
response (55)
87.44 1.01 (1.01, 1.01), <0.001 e e 1.00 (0.99, 1.01), 0.17
Gender
Female (36) 83.11 1 e 1 e 1 e
Male (19) 96.29 1.16 (0.51, 2.64), 0.72 1.12 (0.57, 2.21), 0.74 0.69 (0.32, 1.51), 0.35
BCG vacc historyz
1e9 yrs (8) 274.13 1 e 1 e 1
10e19 yrs (10) 212.37 0.78 (0.26, 2.32) 0.84 (0.29, 2.42) 1.05 (0.30, 3.73)
20e29 yrs (7) 214.43 0.78 (0.24, 2.59) 0.68 (0.21, 2.16) 1.55 (0.32, 7.35)
Never (30) 38.91 0.14 (0.06, 0.36), <0.001x 0.25 (0.09, 0.69), <0.001x 0.29 (0.07, 1.12), >0.05x
ML ratio (43) 1.08¶ (0.71, 1.65), 0.72 1.14¶ (0.81, 1.59), 0.45 1.04¶ (0.73, 1.47), 0.83
Using a similar analysis of GM of the IFN-g response by ML ratio as in Table 2; GM for the 24 week response for a ML ratio of 0.1 and 0.3 were 125.08 and 126.01, respectively.
The GM ratio for the baseline IFN-g response covariate in the partially adjusted analysis is not included here, but all were similar to the unadjusted analysis value
(approximately 1 and p-value<0.05). Abbreviations: IFN-g ¼ Interferon gamma; vacc ¼ vaccination; GM ¼ geometric mean; yrs ¼ years; ML ¼ Monocyte/lymphocyte.
* Adjusted for all variables in the model.
y Due to missing ML ratio data.
z Prior to BCG vaccination.
x p-value for all categories of BCG vaccination history covariate using an ANOVA summary.
¶ The value of the change in GM of the 24 week response for an increase in 0.1 of ML ratio.
Table 5
Short-term prospective (STP) analysis: results of the linear regression analysis on peak IFN-g response.
Peak IFN-g response measured over 24 week follow-up
Covariates (n) Geometric mean of
peak IFN-g response
Unadjusted GM ratio (95% CI),
p-value
Partially adjusted (for baseline IFN-g
response) GM ratio (95% CI), p-value
Fully adjusted* GM ratio (95% CI),
p-value (n ¼ 43y)
Baseline IFN-g response (55) 343.08 1.00 (1.00, 1.01), <0.001 e e 1.00 (0.99, 1.01), 0.14
Gender
Female (36) 336.38 1 e 1 e 1 e
Male (19) 356.90 1.06 (0.64, 1.76), 0.81 1.05 (0.68, 1.59), 0.83 0.89 (0.58, 1.36), 0.57
BCG vacc historyz
1e9 yrs (8) 853.93 1 e 1 e 1
10e19 yrs (10) 595.42 0.70 (0.38, 1.28) 0.71 (0.39, 1.30) 0.72 (0.35, 1.45)
20e29 yrs (7) 588.23 0.70 (0.36, 1.32) 0.65 (0.34, 1.24) 0.75 (0.32, 1.76)
Never (30) 201.06 0.24 (0.14, 0.39), <0.001x 0.29 (0.16, 0.51), <0.001x 0.32 (0.15, 0.68), <0.001x
ML ratio (43) 1.05¶ (0.82, 1.35), 0.70 1.09¶ (0.89, 1.32), 0.38 1.01 (0.84, 1.22), 0.89
Using a similar analysis of GM of the IFN-g response by ML ratio as in Table 2; GM for the peak response for a ML ratio of 0.1 and 0.3 were 536.34 and 564.72, respectively. The
GM ratio for the baseline IFN-g response covariate in the partially adjusted analysis is not included here, but all were similar to the unadjusted analysis value (approximately 1
and p-value < 0.05). Abbreviations: IFN-g ¼ Interferon gamma; vacc ¼ vaccination; GM ¼ geometric mean; yrs ¼ years; ML ¼ Monocyte/lymphocyte.
* Adjusted for all variables in the model.
y Due to missing ML ratio data.
z Prior to BCG vaccination.
x p-value for all categories of BCG vaccination history covariate using an ANOVA summary.
¶ The value of the change in GM of the peak response for an increase in 0.1 of ML ratio.
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S.J. Rhodes et al. / Tuberculosis 96 (2016) 37e4342required to protect against TB disease and in males, a higher im-
mune response may lead to detrimental exaggerated inﬂamma-
tory responses [25].
There is uncertainty in the duration of protection of efﬁcacy
following BCG vaccination. In our Long-term retrospective (LTR)
analysis, we found previous BCG vaccination was associated with a
higher IFN-g response at baseline, which supports results from
several previous studies [8,26]. We also found, in both LTR analysis
and short-term prospective (STP) analysis, no difference between
any IFN-g response if vaccinated any time between 10 and 30 years
ago versus less than 10 years ago, suggesting that there may be no
difference in the immune response generated at one year and up to
30 years after primary vaccination. These results suggest that BCG
vaccination induces a durable memory response. However, previ-
ous studies have shown that IFN-g responses following BCG
vaccination can wane [27]. In order to more precisely assess the
possibility of a waning response in our data, the BCG vaccination
history covariate could be stratiﬁed into smaller groupings. How-
ever, with the current dataset size, this would impact on the sta-
tistical power of the analysis. The duration of a BCG immune
response is complex and currently, not fully understood. As such,
more trials to measure this speciﬁc immune response may be
necessary.
In our STP analysis, we found that revaccination with BCG was
associated with an increase in total (AUC) over 24 weeks and peak
(taking into account baseline levels) IFN-g response. However, it
was not associated with higher IFN-g response (when baseline
responses were taken into account) at 24 weeks. Our in-depth
characterization of this short term effect is supported by previous
work at single time points that showed initial increases following
revaccination with BCG [25e27] that were not sustained at 24 [28]
or 52 weeks [29,30]. This suggests that revaccination with BCG has
an impact on overall IFN-g levels in the short term (<24 weeks) but
may have little effect on IFN-g levels long term (>24 weeks).
All other covariates were non-signiﬁcant. This may be due to
small numbers of participants or no association.
Recent evidence has revealed a complex relationship between
ML ratio and risk of TB disease [14]. We explored if this could be
explained by a link between ML ratio and IFN-g responses. How-
ever, our results showed that ML ratio had no association on IFN-g
response in the LTR or STP analyses. This difference could be
explained by HIV status amongst our participant population
compared to previous work [14].
There are a number of limitations of our work. Most impor-
tantly, we chose to use IFN-g-expressing cells as our marker of
immune response. Whilst the presence of IFN-g has been shown
to be important in protection againstM.tb infection [31], it has not
proven to be a correlate of protection for TB disease [32,33]. It is,
however, one of the most commonly used measures of TB vaccine
immunogenicity we have [34]. The use of IFN-g-expressing cells
as our sole indicator of immunogenicity has beneﬁts in its
simplicity, and was the only outcome for which data was available
to us. Other studies are being carried out that may give a more in
depth view of the immune response to BCG in which a more
complex “biosignature” is being investigated [34]. Secondly, our
work was limited to the data available from the seven TB vaccine
trials, which restricted the covariates available and the size of the
participant cohorts. For example, HIV positive and latently infec-
ted individuals were excluded. Thirdly, in the outlined laboratory
procedure [17e20] a 16-h ELISPOT assay was chosen, which may
have potentially missed central memory CD4þ T-cells as they
require a longer period of antigen re-stimulation to generate IFN-
g [35]. As such, our responses may underestimate the true
“memory” cell presence, speciﬁcally at the later time point of 24
weeks.The implications of our results are as follows. Our results show
that previous BCG vaccination generates a higher immune
response and this may complicate the interpretation of immu-
nological results of new TB vaccine clinical trials, and support
stratiﬁcation of vaccine trial results by previous TB vaccination
status, as is carried out previously [17,26]. In addition, if replicated
in future analysis, our results also suggest that future TB vaccine
trials may need to also stratify their analysis by gender. Moreover,
to potentially capitalize on the impact of higher immune response
due to previous vaccination and to improve upon the variable
efﬁcacy of BCG, it has recently been suggested that revaccination
with BCG may increase efﬁcacy [36]. Our ﬁndings showed that
revaccination with BCG, whilst providing a higher IFN-g peak
response, did not increase IFN-g at 24 weeks over the levels
measure in primary-vaccinated participants. This provides more
evidence to support the WHO policy not to revaccinate with
BCG [37].
As an extension to our analysis, the time between the long-
term retrospective (LTR) and short-term prospective (STP) anal-
ysis could be considered (for example, a number of years via a
phase II/III clinical trial), which is not addressed here. Knowledge
of this may indicate why we see a gender effect in the long term
and not in the short-term and give further insight into the dura-
tion of BCG immunogenicity. Moreover, the link between ML ratio
and TB disease is an exciting development in the search for
informative TB risk factors and further work with additional
detailed datasets should be conducted on the immunology driving
this relationship. To improve upon the methods used in our STP
analysis, mathematical models could be adopted to explore the
underlying mechanisms behind the dynamics. The impact of the
covariates on key immune system parameters would then be
analysed.
5. Conclusion
The research conducted in this analysis aimed to establish,
using new detailed mycobacterial-speciﬁc immune response data,
which, if any, individual level covariates alter the immune
response over the long term or shortly after BCG vaccination. This
analysis suggests that previous BCG vaccination and gender are
associated with durable IFN-g responses. The results of this
analysis imply that future vaccine trials should consider strati-
fying the trial population for analysis by gender and BCG vacci-
nation history.
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